How should I manage an acute gout flare, including first‑line NSAID therapy, colchicine dosing, steroid options, and initiation of urate‑lowering treatment after the attack?

Management of Acute Gout Flares

Initiate pharmacologic therapy within 24 hours of symptom onset using NSAIDs, colchicine, or corticosteroids as first-line monotherapy, with drug selection guided by renal function, cardiovascular risk, gastrointestinal comorbidities, and drug interactions. 1, 2

Timing of Treatment Initiation

• Start treatment within 12–24 hours of symptom onset to achieve maximum therapeutic benefit; delays beyond 24 hours markedly reduce the effectiveness of all anti-inflammatory agents. 1, 2
• Colchicine must be initiated within 36 hours of symptom onset—efficacy declines sharply after this window and should not be started beyond this timeframe. 1, 2

First-Line Treatment Selection Algorithm

Step 1: Assess Renal Function

• If eGFR < 30 mL/min (severe renal impairment): Use oral prednisone 30–35 mg daily for 5 days as first-line therapy; both NSAIDs and colchicine are contraindicated due to risk of acute kidney injury and fatal colchicine toxicity. 1, 2, 3
• If eGFR 30–59 mL/min (moderate renal impairment): NSAIDs carry high risk of acute kidney injury; colchicine requires dose reduction to 0.6 mg once daily for prophylaxis with close monitoring during acute dosing; corticosteroids are the safest option. 2
• If eGFR ≥ 60 mL/min (normal renal function): NSAIDs, colchicine, or corticosteroids are all appropriate first-line options. 1, 2

Step 2: Screen for Drug Interactions (Colchicine)

• Absolute contraindication to colchicine: Concurrent use of strong CYP3A4 or P-glycoprotein inhibitors (clarithromycin, erythromycin, cyclosporine, ketoconazole, ritonavir, verapamil), especially with any degree of renal or hepatic impairment—this combination can cause fatal toxicity. 1, 2, 4
• If these inhibitors are present: Select NSAIDs or corticosteroids instead. 2, 4

Step 3: Evaluate Cardiovascular and Gastrointestinal Risk (NSAIDs)

• NSAIDs are contraindicated in: Heart failure, established cardiovascular disease, active or recent peptic ulcer disease/GI bleeding, cirrhosis, hepatic impairment, or concurrent anticoagulation therapy. 1, 2, 3
• If any of these conditions are present: Use colchicine (if no drug interactions) or corticosteroids. 2, 3

Step 4: Consider Joint Involvement

• For monoarticular or oligoarticular gout (1–2 large, accessible joints): Intra-articular corticosteroid injection (triamcinolone 40 mg for knee, 20–30 mg for ankle) provides targeted therapy with minimal systemic effects. 1, 2, 3
• For polyarticular gout (≥ 4 joints) or severe attacks: Initiate combination therapy (see below). 1, 2

Specific Dosing Regimens

NSAIDs

• Use full FDA-approved anti-inflammatory doses throughout the entire attack without early tapering: 1, 2, 4
  • Naproxen 500 mg twice daily
  • Indomethacin 50 mg three times daily
  • Sulindac 200 mg twice daily
• No single NSAID has demonstrated superior efficacy; selection should be based on availability and individual tolerance. 2
• Continue at full dose until complete resolution of the gout attack; reducing the dose early compromises treatment success. 1, 2

Colchicine (Low-Dose Regimen)

• Loading dose: 1.2 mg orally at the first sign of flare, followed 1 hour later by 0.6 mg (total 1.8 mg over one hour). 1, 2, 4
• Maintenance dosing: After a 12-hour pause, resume 0.6 mg once or twice daily until the attack resolves. 1, 2
• This low-dose regimen achieves ≥50% pain reduction (number needed to treat = 3–5) and causes significantly fewer gastrointestinal adverse effects (23% diarrhea) compared with obsolete high-dose regimens (77% diarrhea). 2
• Do not use the outdated regimen of 0.5 mg every 2 hours until relief or toxicity—it causes severe diarrhea in most patients without added benefit. 2

Corticosteroids

• Oral prednisone: 0.5 mg/kg per day (approximately 30–35 mg for average adults) for 5–10 days at full dose then stop abruptly, or give for 2–5 days at full dose followed by a 7–10 day taper. 1, 2, 3
• Level A evidence shows oral corticosteroids are equally effective as NSAIDs but result in fewer adverse events (27% vs 63%). 2, 3
• For straightforward monoarticular cases without significant comorbidities, use the simpler 5–10 day course without taper. 2
• For severe attacks, polyarticular involvement, or patients at higher risk for rebound flares, use the tapered approach. 2
• Intramuscular option: Triamcinolone acetonide 60 mg as a single injection for patients unable to take oral medications. 2, 3

Combination Therapy for Severe or Polyarticular Attacks

• Indications: Polyarticular gout (≥ 4 joints), involvement of multiple large joints, or severe pain unresponsive to monotherapy within 24 hours. 1, 2
• Recommended combinations: 1, 2
  • Colchicine + NSAID
  • Oral corticosteroid + colchicine
  • Intra-articular steroid + any oral agent
• Avoid systemic NSAID + systemic corticosteroid due to synergistic gastrointestinal toxicity. 1, 2

Management of Urate-Lowering Therapy During an Acute Flare

• Do not discontinue existing urate-lowering therapy (allopurinol or febuxostat) during an acute flare if the patient is already on it; continue the medication and treat the flare separately. 1, 2
• Do not initiate new urate-lowering therapy during an active gout attack; wait until the flare has completely resolved. 2

Initiation of Urate-Lowering Therapy After the Flare Resolves

When to Start ULT

• Strong indications (initiate after first flare): Subcutaneous tophi, radiographic joint damage, chronic kidney disease stage ≥ 3. 2
• Conditional indications: Patient preference, age < 40 years at onset, serum urate > 9 mg/dL, ≥ 2 attacks per year, or urolithiasis. 2

Allopurinol Initiation Protocol

• Start low: Begin with 100 mg daily (or 50 mg daily if creatinine clearance 30–50 mL/min). 2
• Go slow: Increase by 100 mg every 2–4 weeks until serum urate < 6 mg/dL is achieved. 2
• Typical maintenance dose: 300–600 mg daily; maximum 800 mg daily. 2

Mandatory Colchicine Prophylaxis When Starting ULT

• Colchicine 0.6 mg once or twice daily must be started concurrently with the first dose of allopurinol and continued for at least 6 months. 1, 2, 5
• Duration of prophylaxis: 2
  • Continue for ≥ 6 months, or
  • Continue for 3 months after achieving target serum urate < 6 mg/dL if no tophi are present, and 6 months after reaching target when tophi are present
• High-quality evidence shows colchicine prophylaxis reduces the proportion of patients experiencing flares from 77% to 33% during allopurinol initiation. 2

Alternative Prophylaxis Options

• If colchicine is contraindicated: Use low-dose NSAID with a proton-pump inhibitor (e.g., naproxen 250 mg twice daily with omeprazole 20 mg daily) or low-dose prednisone < 10 mg/day. 2, 6
• Avoid high-dose prednisone (> 10 mg/day) for prophylaxis because it increases adverse effects without additional benefit. 2

Common Pitfalls to Avoid

• Do not delay treatment beyond 24 hours; effectiveness declines sharply. 1, 2
• Do not start colchicine after 36 hours from symptom onset; efficacy drops dramatically—choose NSAIDs or corticosteroids instead. 1, 2
• Do not taper NSAIDs early; maintain full dose throughout the attack. 1, 2
• Do not combine colchicine with strong CYP3A4/P-gp inhibitors in patients with any renal or hepatic impairment due to fatal toxicity risk. 1, 2, 4
• Do not initiate allopurinol at 300 mg daily; starting at a high dose increases risk of flares and hypersensitivity syndrome. 2
• Do not stop urate-lowering therapy during an acute flare if the patient is already on it. 1, 2
• Do not omit colchicine prophylaxis when starting ULT; flare rates roughly double without it. 2